Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
BMS Active Not Yet Recruiting Study icon

Active, Not Recruiting

Trial ID CC-220-MM-001  |   NCT02773030

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Warning icon
Sorry, this study is no longer accepting new participants, but is still ongoing.
You may click the “Check if you qualify” button and answer a few questions about your health to find out if you might be a match to another study.

Summary

  • Phase 1/Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • BMS Active Not Yet Recruiting Study icon
    Active, Not Recruiting

Overview

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 monotherapy and CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combination with DEX and DARA for Newly Diagnosed Multiple Myeloma (NDMM).

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
    1. Relapsed and refractory multiple myeloma (RRMM) participants must have documented disease progression on or within 60 days from the last dose of their last myeloma therapy
      1. Newly diagnosed multiple myeloma (NDMM) participants must have documented diagnosis with previously untreated symptomatic multiple myeloma (MM)
        1. Participants in Cohorts J1 and K are those for whom autologous stem cell transplantation is not planned for initial therapy or are not considered by the investigator as eligible for high-dose chemotherapy and autologous stem cell transplantation

          Exclusion Criteria

          Exclusion Criteria Icon
          :
          • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study
            1. Nonsecretory multiple myeloma
              1. Prior history of malignancies, other than MM and select non-invasive malignancies, unless the participant has been free of the disease for ≥ 5 years Other protocol-defined inclusion/exclusion criteria apply
                Additional Information *

                Treatment Options

                Study Arms

                ASSIGNED INTERVENTION

                Study Arms

                Experimental: Cohort A: CC-220 Monotherapy - Part 1

                ASSIGNED INTERVENTION
                • Drug: CC-220

                Study Arms

                Experimental: Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1

                ASSIGNED INTERVENTION
                • Drug: CC-220, Dexamethasone

                Study Arms

                Experimental: Cohort C: CC-220 Monotherapy in RRMM - Part 2

                ASSIGNED INTERVENTION
                • Drug: CC-220

                Study Arms

                Experimental: Cohort D: CC-220 in combination with Dexamethasone - Part 2

                ASSIGNED INTERVENTION
                • Drug: CC-220, Dexamethasone

                Study Arms

                Experimental: Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1

                ASSIGNED INTERVENTION
                • Drug: Dexamethasone, CC-220, Daratumumab

                Study Arms

                Experimental: Cohort F: CC-220 with DEX and bortezomib - Part 1

                ASSIGNED INTERVENTION
                • Drug: Dexamethasone, CC-220, Bortezomib

                Study Arms

                Experimental: Cohort G1: CC-220 in combination with CFZ and DEX - Part 1

                ASSIGNED INTERVENTION
                • Drug: Dexamethasone, CC-220, Carfilzomib

                Study Arms

                Experimental: Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1

                ASSIGNED INTERVENTION
                • Drug: Carfilzomib, Dexamethasone, CC-220

                Study Arms

                Experimental: Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2

                ASSIGNED INTERVENTION
                • Drug: CC-220, Dexamethasone

                Study Arms

                Experimental: Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2

                ASSIGNED INTERVENTION
                • Drug: CC-220, Dexamethasone, Bortezomib

                Study Arms

                Experimental: Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2

                ASSIGNED INTERVENTION
                • Drug: CC-220, Dexamethasone, Bortezomib

                Study Arms

                Experimental: Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible - Part 2

                ASSIGNED INTERVENTION
                • Drug: CC-220, Daratumumab, Dexamethasone

                Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you